PATENT CLAIM ANALYSIS

Application Number: 16036020
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "252010"]

Abstract:
Disclosed herein are β-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.

Claim (Index 9):
The method of  claim 1 , wherein said administration is oral administration.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 95.0
- Lexical Diversity: 1.55263
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14388494', '15199207', '12941468', '14977251', '15223312']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7379225141171389
- 35 USC 102 Novelty (BERT): 0.5400239137313307
- Combined Prediction Score: 0.7181326540785582
- Mean Citation Score: 239.901052
- Max Citation Score: 264.54
- Similarity Product: 106.80959452807905

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test